Analysis Khiron Life Sciences Corp. (KHRNF)
5/28/2024
Analysis of Khiron Life Sciences Corp. (KHRNF)
Khiron Life Sciences Corp. (KHRNF) has shown a recent increase in price from 0.01145 to 0.01150. The Relative Strength Index (RSI) is currently at a high level of 96.93, indicating that the stock may be overbought. The Moving Average Convergence Divergence (MACD) indicator is slightly positive at 0.00019, with the MACD line above the signal line.Looking at the historical data, the stock has been trading around 0.009 in the past few days with consistent RSI and MACD values. The Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) are all around 0.009, indicating stability in the stock price.
Overall, Khiron Life Sciences Corp. is currently showing signs of being overbought based on the RSI indicator. Traders and investors may want to exercise caution and monitor the stock closely for any potential reversal in the price trend.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 11%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. It is important to note that these are analyst estimates and actual performance may vary.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the lowest estimate at $164, the highest at $250, and the average at $202.26. The current price is $191.57, which falls below the average and median estimates. Investors should consider these forecasts along with other factors when making decisions about buying or selling the security.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits for a specific company.In terms of financials, the company has strong cash flow with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet shows a total cash of $67.15 billion, total debt of $104.59 billion, and a current ratio of 1.037. The profit margin is 26.31% and the company's fiscal year ends on September 30, 2023. The income statement reveals an EBITDA of $131.39 billion, revenue of $381.62 billion, and a diluted EPS of 6.44.
Moving on to stock statistics, the company has a short ratio of 1.66, with 94.31 million shares shorted out of 15.31 billion float shares. The average 10-day volume is 52.90 million shares, while the average 90-day volume is 62.82 million shares. The stock has a market capitalization of $2.91 trillion.
Valuation metrics show a PEG ratio of 26.21, forward P/E of 26.21, trailing P/E of 29.43, and a price to book ratio of 39.18. The stock has an enterprise value of $2.95 trillion, price to sales ratio of 7.62, enterprise to EBITDA ratio of 22.75, and enterprise to revenue ratio of 7.73.
The stock price summary includes a beta of 1.26, 50-day moving average of $173.69, 200-day moving average of $180.79, and a 52-week range from $164.08 to $199.62.
Lastly, dividends and splits information indicate a payout ratio of 14.93%, with a forward annual dividend rate of $1 and a trailing annual dividend rate of $0.97. The company's dividend yield is 0.53% and the last split date was on August 31, 2020, with a 4-for-1 split.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:1. Fiscal Year 2020: Sales of $274,515,000,000
2. Fiscal Year 2021: Sales of $365,817,000,000
3. Fiscal Year 2022: Sales of $394,328,000,000
4. Fiscal Year 2023: Sales of $383,285,000,000
From the data, we can observe the following trends:
- There was a steady increase in revenue from 2020 to 2022, with a significant jump between 2021 and 2022.
- However, in 2023, there was a slight decrease in revenue compared to the previous year.
- Overall, the company has shown growth in sales over the past four years, with some fluctuations in the most recent year.
These revenue figures provide insights into the company's performance and can be used to analyze its financial health and growth trajectory.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, from $323.9 billion in 2018 to $352.8 billion in 2023.
2. Current assets have fluctuated but generally increased, with the highest value in 2023 at $143.6 billion.
3. Non-current assets have also shown an increasing trend, reaching $209 billion in 2023.
4. Total liabilities have been increasing steadily, from $255.4 billion in 2018 to $290.4 billion in 2023.
5. Shareholders' equity has shown fluctuations but has increased overall, from $107.1 billion in 2018 to $62.1 billion in 2023.
6. The company has been investing more in non-current assets and has been relying more on liabilities rather than equity to finance its operations.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show significant changes each year, with fluctuations in common dividends, stock repurchases, and debt issuances.
6. Investing activities also vary, with changes in acquisitions, investments, and capital expenditures.
7. Overall, the company's financial performance seems to be stable, with some fluctuations in key financial metrics over the years.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39
Based on these estimates, we can see a generally positive trend in the expected earnings per share for both the upcoming quarters and the next two years. The average estimates show an increase compared to the year-ago EPS figures, indicating potential growth in earnings for the company.
MACD of KHRNF
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
